Brief: FDA Approves Pfizer’S Ibrance Regimen For HR+,HER2+ Metastatic Breast Cancer Frontline Maintenance
24/06/2026 20:00
BRIEF-FDA Approves Pfizer’S Ibrance Regimen For HR+,HER2+ Metastatic Breast Cancer Frontline Maintenance June 24 (Reuters) - Pfizer Inc PFE.N:
FDA APPROVES PFIZER’S IBRANCE REGIMEN FOR HR+, HER2+ METASTATIC BREAST CANCER FRONTLINE MAINTENANCE
Source text: ID:nBw8Y4X5Ma
Further company coverage: PFE.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pfizer
See all newsU.S. STOCKS ON THE MOVE-Chip stocks, Unicycive, Roblox
U.S. STOCKS ON THE MOVE-AMD, Roblox, Olin
Eli Lilly, Pfizer slip after US House panel probing China clinical trials
US House committee opens investigation into Merck, AbbVie China drug trials (updated)
Brief: U.S. House Committee Sends Letters To Pfizer, Eli Lilly & Bristol Myers Squibb Probing China Drug Trials